BackgroundXp11.2 translocation renal cell carcinoma (Xp11.2 RCC) is a rare malignancy which is more common in children than in adults. It manifests with an aggressive course in adults and relatively indolent in children. Prognostic studies for adult patients are scare for the rarity of the disease; and the prognostic value of preoperative plasma fibrinogen level awaits further illumination.MethodsThis retrospective single-center study enrolled 24 consecutive newly diagnosed Xp11.2 RCC adult patients. Clinical presentations, baseline laboratory results and follow-up data were collected. Possible risk factors for progression free survival (PFS) and overall survival (OS) were first scanned with chi-square tests and t-tests to compare patients who suffered from progression or death and who did not. Independent risk factors for survival were further investigated with multivariate Cox regression.ResultsTwenty-four adult patients (median age 32, range 16-73), with a male-to-female ratio of 12:12, was included from 2010.4 to 2020.3. After a mean follow-up of 35.7months, seven patients died. With univariate analysis, higher C-reactive protein-to-albumin ratio (p=0.028), higher baseline fibrinogen level (p=0.006), and presence of distant metastasis(p=0.007) were associated with progression of disease; higher preoperative fibrinogen level (p=0.014) and distant metastasis (p= 0.020) were associated with death. With multivariate Cox regression, only baseline fibrinogen level (p=0.001) was identified as an independent risk factor for progression free survival; meanwhile, fibrinogen level (p= 0.048) and distant metastasis (p= 0.043) were identified as independent risk factors for survival.ConclusionsPreoperative plasma fibrinogen level, a routinely tested parameter before surgery, is a promising tool for risk stratification in adult patients with Xp11.2 RCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.